237 related articles for article (PubMed ID: 32041867)
1. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning.
Bruno PM; Lu M; Dennis KA; Inam H; Moore CJ; Sheehe J; Elledge SJ; Hemann MT; Pritchard JR
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4053-4060. PubMed ID: 32041867
[TBL] [Abstract][Full Text] [Related]
2. Transcription-associated topoisomerase 2α (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands.
Bossaert M; Pipier A; Riou JF; Noirot C; Nguyên LT; Serre RF; Bouchez O; Defrancq E; Calsou P; Britton S; Gomez D
Elife; 2021 Jun; 10():. PubMed ID: 34180392
[TBL] [Abstract][Full Text] [Related]
3. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
4. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase levels determine chemotherapy response in vitro and in vivo.
Burgess DJ; Doles J; Zender L; Xue W; Ma B; McCombie WR; Hannon GJ; Lowe SW; Hemann MT
Proc Natl Acad Sci U S A; 2008 Jul; 105(26):9053-8. PubMed ID: 18574145
[TBL] [Abstract][Full Text] [Related]
6. The rRNA synthesis inhibitor CX-5461 may induce autophagy that inhibits anticancer drug-induced cell damage to leukemia cells.
Okamoto S; Miyano K; Kajikawa M; Yamauchi A; Kuribayashi F
Biosci Biotechnol Biochem; 2020 Nov; 84(11):2319-2326. PubMed ID: 32799625
[TBL] [Abstract][Full Text] [Related]
7. The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.
Bridewell DJ; Porter AC; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 2008 Oct; 62(5):753-62. PubMed ID: 18175117
[TBL] [Abstract][Full Text] [Related]
8. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
Drummond CJ; Finlay GJ; Broome L; Marshall ES; Richardson E; Baguley BC
Invest New Drugs; 2011 Oct; 29(5):1102-10. PubMed ID: 20567995
[TBL] [Abstract][Full Text] [Related]
9. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
10. Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461.
Li G; Shen J; Cao J; Zhou G; Lei T; Sun Y; Gao H; Ding Y; Xu W; Zhan Z; Chen Y; Huang H
J Exp Clin Cancer Res; 2018 Apr; 37(1):78. PubMed ID: 29631594
[TBL] [Abstract][Full Text] [Related]
11. Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors.
Legina MS; Nogueira JJ; Kandioller W; Jakupec MA; González L; Keppler BK
J Biol Inorg Chem; 2020 May; 25(3):451-465. PubMed ID: 32193613
[TBL] [Abstract][Full Text] [Related]
12. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
Chen HH; Chang HH; Chang JY; Tang YC; Cheng YC; Lin LM; Cheng SY; Huang CH; Sun MW; Chen CT; Kuo CC
Free Radic Biol Med; 2017 Dec; 113():505-518. PubMed ID: 29080842
[TBL] [Abstract][Full Text] [Related]
13. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
14. CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer.
Makhale A; Nanayakkara D; Raninga P; Khanna KK; Kalimutho M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071360
[TBL] [Abstract][Full Text] [Related]
15. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Hawtin RE; Stockett DE; Byl JA; McDowell RS; Nguyen T; Arkin MR; Conroy A; Yang W; Osheroff N; Fox JA
PLoS One; 2010 Apr; 5(4):e10186. PubMed ID: 20419121
[TBL] [Abstract][Full Text] [Related]
17. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
[TBL] [Abstract][Full Text] [Related]
18. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
[TBL] [Abstract][Full Text] [Related]
19. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
20. Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells.
Jeon KH; Yu HV; Kwon Y
Biochim Biophys Acta Gen Subj; 2018 May; 1862(5):1126-1133. PubMed ID: 29425806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
